Impact of Statin Use on Development of New-Onset Diabetes Mellitus in Asian Population

American Journal of Cardiology

Volumn 117, Issue 3, 2016, Pages 382-387

  Rha, Seung Woon ^a   Choi, Byoung Geol ^b   Seo, Hong Seog ^c   Park, Sang Ho ^a   Park, Ji Young ^d   Chen, Kang Yin ^e   Park, Yoonjee ^a   Choi, Se Yeon ^b   Shim, Min Suk ^a   Kim, Ji Bak ^f   Park, Taeshik ^g   Park, Joonhyung ^h   Lee, Jae Joong ^a   Park, Eun Jin ^a   Park, Sung Hun ⁱ   Choi, Jah Yeon ^a   Lee, Sunki ^a   Na, Jin Oh ^a   Choi, Cheol Ung ^a   Lim, Hong Euy ^a   Kim, Jin Won ^a   Kim, Eung Ju ^a   Park, Chang Gyu ^a   Oh, Dong Joo ^a   more..

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d Eulji General Hospital   (South Korea)

^e SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^f Sejong General Hospital   (South Korea)

^g WEISS MEMORIAL HOSPITAL   (United States)

^h Korea Worker's Compensation and Welfare Service   (South Korea)

ⁱ Soonchunhyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID;

ADULT; AGE; ARTICLE; ASIAN; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIURETIC THERAPY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW ONSET DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; BLOOD; CARDIOVASCULAR DISEASES; GLUCOSE BLOOD LEVEL; INCIDENCE; METABOLISM; PROGNOSIS; PROPENSITY SCORE; RISK ASSESSMENT; RISK FACTOR; SOUTH KOREA;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84973408394     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.11.009     Document Type: Article

References (22)

1. 1 Goldfine, A.B., Statins: is it really time to reassess benefits and risks?. N Engl J Med 366 (2012), 1752–1755.
2. 2 Brault, M., Ray, J., Gomez, Y.H., Mantzoros, C.S., Daskalopoulou, S.S., Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 63 (2014), 735–745.
3. 3 Sattar, N., Taskinen, M.R., Statins are diabetogenic–myth or reality?. Atheroscler Suppl 13 (2012), 1–10.
4. 4 Rajpathak, S.N., Kumbhani, D.J., Crandall, J., Barzilai, N., Alderman, M., Ridker, P.M., Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32 (2009), 1924–1929.
5. 5 Sattar, N., Preiss, D., Murray, H.M., Welsh, P., Buckley, B.M., de Craen, A.J., Seshasai, S.R., McMurray, J.J., Freeman, D.J., Jukema, J.W., Macfarlane, P.W., Packard, C.J., Stott, D.J., Westendorp, R.G., Shepherd, J., Davis, B.R., Pressel, S.L., Marchioli, R., Marfisi, R.M., Maggioni, A.P., Tavazzi, L., Tognoni, G., Kjekshus, J., Pedersen, T.R., Cook, T.J., Gotto, A.M., Clearfield, M.B., Downs, J.R., Nakamura, H., Ohashi, Y., Mizuno, K., Ray, K.K., Ford, I., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010), 735–742.
6. 6 Preiss, D., Seshasai, S.R., Welsh, P., Murphy, S.A., Ho, J.E., Waters, D.D., DeMicco, D.A., Barter, P., Cannon, C.P., Sabatine, M.S., Braunwald, E., Kastelein, J.J., de Lemos, J.A., Blazing, M.A., Pedersen, T.R., Tikkanen, M.J., Sattar, N., Ray, K.K., Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 305 (2011), 2556–2564.
7. 7 Culver, A.L., Ockene, I.S., Balasubramanian, R., Olendzki, B.C., Sepavich, D.M., Wactawski-Wende, J., Manson, J.E., Qiao, Y., Liu, S., Merriam, P.A., Rahilly-Tierny, C., Thomas, F., Berger, J.S., Ockene, J.K., Curb, J.D., Ma, Y., Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 172 (2012), 144–152.
8. 8 Ridker, P.M., Pradhan, A., MacFadyen, J.G., Libby, P., Glynn, R.J., Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380 (2012), 565–571.
9. 9 Carter, A.A., Gomes, T., Camacho, X., Juurlink, D.N., Shah, B.R., Mamdani, M.M., Risk of incident diabetes among patients treated with statins: population based study. Br Med J, 346, 2013, f2610.
10. 10 Chen, C.W., Chen, T.C., Huang, K.Y., Chou, P., Chen, P.F., Lee, C.C., Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an Asian country. PLoS One, 8, 2013, e71817.
11. 11 Danaei, G., Garcia Rodriguez, L.A., Fernandez Cantero, O., Hernan, M.A., Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 36 (2013), 1236–1240.
12. 12 Park, J.Y., Rha, S.W., Choi, B., Choi, J.W., Ryu, S.K., Kim, S., Noh, Y.K., Choi, S.Y., Akkala, R.G., Li, H., Ali, J., Xu, S., Ngow, H.A., Lee, J.J., Lee, G.N., Kim, J., Lee, S., Na, J.O., Choi, C.U., Lim, H.E., Kim, J.W., Kim, E., Park, C.G., SeogSeo, H., Oh, D.J., Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: three-year clinical outcomes. Int J Cardiol 184 (2015), 502–506.
13. 13 Wang, K.L., Liu, C.J., Chao, T.F., Chen, S.J., Wu, C.H., Huang, C.M., Chang, C.C., Wang, K.F., Chen, T.J., Lin, S.J., Chiang, C.E., Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. Am J Cardiol 113 (2014), 631–636.
14. 14 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 36:Suppl 1 (2013), S67–S74.
15. 15 Metz, S.A., Rabaglia, M.E., Stock, J.B., Kowluru, A., Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J 295:Pt 1 (1993), 31–40.
16. 16 McGuire, T.F., Xu, X.Q., Corey, S.J., Romero, G.G., Sebti, S.M., Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. Biochem Biophys Res Commun 204 (1994), 399–406.
17. 17 Öhrvall, M., Lithell, H., Johansson, J., Vessby, B., A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 44 (1995), 212–217.
18. 18 Koh, K.K., Letter by Koh regarding article, “Statins and risk of new-onset diabetes mellitus”. Circulation, 127, 2013, e837.
19. 19 Lim, S., Sakuma, I., Quon, M.J., Koh, K.K., Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol 167 (2013), 1696–1702.
20. 20 Henriksbo, B.D., Lau, T.C., Cavallari, J.F., Denou, E., Chi, W., Lally, J.S., Crane, J.D., Duggan, B.M., Foley, K.P., Fullerton, M.D., Tarnopolsky, M.A., Steinberg, G.R., Schertzer, J.D., Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63 (2014), 3742–3747.
21. 21 Kang, D.O., Seo, H.S., Choi, B.G., Lee, E., Kim, J.P., Lee, S.K., Im, S.I., Na, J.O., Choi, C.U., Lim, H.E., Kim, J.W., Kim, E.J., Rha, S.W., Park, C.G., Oh, D.J., Absolute change in fasting plasma glucose over 12 months is associated with 2-year and 5-year major adverse cardiovascular events in patients with drug-eluting stent implants. Int J Cardiol 179 (2015), 146–152.
22. 22 Twito, O., Ahron, E., Jaffe, A., Afek, S., Cohen, E., Granek-Catarivas, M., Klein, P., Hermoni, D., New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization. Diabetes Care 36 (2013), 3425–3429.